Chen Qingke, Li Lei, Wang Gongxian, Hu Jieping, Sun Ting, Fu Bin
Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Department of Anesthesiology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
Oncotarget. 2017 Jul 18;8(29):48263-48271. doi: 10.18632/oncotarget.17593.
The clinical implications of histological variants in urothelial carcinoma of the bladder has been a subject of significant controversy with many unanswered questions that remain. To clarify whether histological variants presage poor prognosis for patients suffering from urothelial carcinoma of the bladder, we scoured through various electronic databases such as Medline, Web of Knowledge, and the Cochrane Library up to August 18, 2016. Experts were consulted, and references from relevant articles were scanned. We identified thirteen eligible studies which met the inclusion criteria, including 9,533 participants. The existing evidence indicates that histological variants in urothelial carcinoma of the bladder patients do not alter their prognosis.
膀胱尿路上皮癌组织学变异的临床意义一直是一个存在重大争议的话题，仍有许多未解决的问题。为了阐明组织学变异是否预示着膀胱尿路上皮癌患者的预后不良，我们检索了各种电子数据库，如截至2016年8月18日的Medline、Web of Knowledge和Cochrane图书馆。咨询了专家，并浏览了相关文章的参考文献。我们确定了13项符合纳入标准的合格研究，包括9533名参与者。现有证据表明，膀胱尿路上皮癌患者的组织学变异不会改变其预后。
